Arcus Historical Financial Ratios
RCUS Stock | USD 16.41 0.75 4.37% |
Arcus Biosciences is presently reporting on over 97 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 5.49, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.34 will help investors to properly organize and evaluate Arcus Biosciences financial condition quickly.
Arcus |
About Arcus Financial Ratios Analysis
Arcus BiosciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Arcus Biosciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Arcus financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Arcus Biosciences history.
Arcus Biosciences Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Arcus Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Arcus Biosciences sales, a figure that is much harder to manipulate than other Arcus Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from Arcus Biosciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Arcus Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.At this time, Arcus Biosciences' PTB Ratio is comparatively stable compared to the past year. Capex To Depreciation is likely to gain to 6.41 in 2024, whereas Days Sales Outstanding is likely to drop 114.59 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 710.21 | 140.13 | 131.03 | 114.59 | PTB Ratio | 3.34 | 2.27 | 3.06 | 3.39 |
Arcus Biosciences fundamentals Correlations
Click cells to compare fundamentals
Arcus Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arcus Biosciences fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 29.51 | 18.35 | 7.33 | 13.29 | 12.08 | 11.48 | |
Ptb Ratio | 2.7 | 2.83 | 3.34 | 2.27 | 3.06 | 3.39 | |
Days Sales Outstanding | 3.21 | 8.0 | 710.21 | 140.13 | 131.03 | 114.59 | |
Book Value Per Share | 3.74 | 9.17 | 12.13 | 9.13 | 6.24 | 5.49 | |
Free Cash Flow Yield | (0.17) | 0.076 | (0.1) | 0.29 | (0.23) | (0.22) | |
Operating Cash Flow Per Share | (1.68) | 2.03 | (3.69) | 6.08 | (4.14) | (3.93) | |
Stock Based Compensation To Revenue | 0.6 | 0.28 | 0.14 | 0.58 | 0.62 | 0.34 | |
Capex To Depreciation | 1.02 | 0.54 | 0.73 | 6.79 | 6.11 | 6.41 | |
Pb Ratio | 2.7 | 2.83 | 3.34 | 2.27 | 3.06 | 3.39 | |
Ev To Sales | 25.65 | 16.31 | 7.25 | 12.53 | 11.09 | 10.53 | |
Free Cash Flow Per Share | (1.72) | 1.97 | (4.07) | 5.92 | (4.46) | (4.24) | |
Roic | (0.49) | (0.23) | 0.0623 | (0.43) | (0.75) | (0.71) | |
Net Income Per Share | (1.73) | (2.13) | 0.76 | (3.71) | (4.15) | (3.94) | |
Payables Turnover | 16.68 | 10.14 | 0.69 | 0.7 | 0.81 | 0.76 | |
Sales General And Administrative To Revenue | 1.68 | 0.55 | 0.19 | 0.93 | 1.07 | 1.9 | |
Research And Ddevelopement To Revenue | 5.23 | 2.06 | 0.67 | 2.57 | 2.91 | 2.76 | |
Capex To Revenue | 0.13 | 0.0394 | 0.0681 | 0.11 | 0.21 | 0.19 | |
Cash Per Share | 4.3 | 13.3 | 7.2 | 14.01 | 10.26 | 6.46 | |
Pocfratio | (6.03) | 12.79 | (10.96) | 3.4 | (4.62) | (4.85) | |
Capex To Operating Cash Flow | (0.0262) | 0.0275 | (0.1) | 0.0274 | (0.0784) | (0.0824) | |
Pfcf Ratio | (5.87) | 13.16 | (9.94) | 3.5 | (4.28) | (4.5) | |
Days Payables Outstanding | 21.88 | 36.0 | 530.72 | 521.43 | 18.25 | 17.34 | |
Roe | (0.46) | (0.23) | 0.063 | (0.41) | (0.66) | (0.7) | |
Ev To Operating Cash Flow | (5.24) | 11.37 | (10.83) | 3.2 | (4.24) | (4.45) | |
Pe Ratio | (5.83) | (12.19) | 52.95 | (5.58) | (4.6) | (4.37) | |
Return On Tangible Assets | (0.18) | (0.37) | (0.15) | 0.0333 | (0.2) | (0.29) | |
Ev To Free Cash Flow | (5.1) | 11.69 | (9.83) | 3.29 | (3.93) | (4.13) | |
Earnings Yield | (0.17) | (0.082) | 0.0189 | (0.18) | (0.22) | (0.23) | |
Net Debt To E B I T D A | 0.71 | 1.34 | (0.5) | 0.34 | 0.41 | 0.39 | |
Current Ratio | 8.49 | 6.04 | 4.1 | 5.53 | 4.52 | 4.29 | |
Tangible Book Value Per Share | 3.74 | 9.17 | 12.13 | 9.13 | 6.24 | 5.49 | |
Receivables Turnover | 113.64 | 45.65 | 0.51 | 2.6 | 2.79 | 2.65 | |
Graham Number | 12.07 | 20.96 | 14.45 | 27.59 | 24.14 | 13.22 | |
Shareholders Equity Per Share | 3.74 | 9.17 | 12.13 | 9.13 | 6.24 | 5.49 | |
Capex Per Share | 0.11 | 0.0439 | 0.0558 | 0.38 | 0.32 | 0.34 | |
Graham Net Net | 3.4 | 8.33 | (1.06) | 3.71 | 2.13 | 4.08 | |
Revenue Per Share | 0.34 | 1.41 | 5.52 | 1.56 | 1.58 | 1.22 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.